Reaffirms 2018 Guidance and Provides 3-Year Financial Goals and
Objectives
WAYNE, Pa.--(BUSINESS WIRE)--May 11, 2018--
Teleflex Incorporated (NYSE: TFX), a leading global provider of medical
devices, will provide an update on its business and address its 3-year
business growth strategy and financial goals during its 2018 Analyst &
Investor Day today in New York City. A live webcast of the event
presentations will begin at 9:00 a.m. ET and the accompanying
presentation materials will be available at that time on the Company’s
web site at www.teleflex.com.
“Teleflex is pleased to provide our 3-year growth strategy and share an
in-depth update on the key aspects of our business that we believe will
be instrumental to our operating and financial performance over this
period,” said Liam Kelly, President and Chief Executive Officer. “With a
large global infrastructure, strong competitive positions in promising
medical specialty markets and a strategic focus on offering solutions
that address major healthcare challenges around the world, the Company
is well-positioned to capitalize on the many growth opportunities that
are currently emerging within our marketplace.”
Mr. Kelly continued, “Building on this foundation, we will continue to
pursue business optimization opportunities that drive non-revenue
dependent margin improvements and target acquisition candidates that
complement our existing business, have differentiated products and can
strengthen our financial profile. We expect our 3-year growth strategy
to accelerate the Company’s organic growth, deliver gross and operating
margin expansion and generate strong free cash flows.”
2018 OUTLOOK
The Company reaffirms its previously provided financial guidance for
2018:
-
On a GAAP basis, revenues in 2018 are expected to increase 15% to 16%
over the prior year, reflecting the anticipated 3% favorable impact of
foreign currency exchange rate fluctuations. On a constant currency
basis, the Company estimates that revenues for full year 2018 will
increase 12% to 13%.
-
The Company expects full year 2018 GAAP diluted earnings per share
from continuing operations to be between $5.45 and $5.55, representing
an increase of 63.7% to 66.7% over 2017. The Company expects adjusted
diluted earnings per share from continuing operations to be between
$9.70 and $9.90 for full year 2018, representing an increase of 15.5%
to 17.9% over 2017, reflecting the Company’s expectation of an
approximately 5% positive impact from foreign currency exchange rate
fluctuations.
3-YEAR FINANCIAL GOALS AND OBJECTIVES
-
Average organic constant currency revenue growth of between 6% and 7%
from 2019 through 2021
-
Adjusted gross margin of between 60% and 61% by 2021
-
Adjusted operating margin of between 30% and 31% by 2021
-
Average adjusted tax rate of between 16% and 17.5% from 2019 through
2021
-
Average free cash flow generation of between $500 million and $550
million from 2019 through 2021
FORECASTED 2018 CONSTANT CURRENCY REVENUE GROWTH RECONCILIATION
|
|
Low |
|
|
|
High |
|
|
|
|
|
|
|
|
2018 GAAP revenue growth
|
|
15
|
|
%
|
|
|
|
16
|
|
%
|
|
|
|
|
|
|
|
|
Estimated impact of foreign currency exchange rate fluctuations
|
|
(3
|
)
|
%
|
|
|
|
(3
|
)
|
%
|
|
|
|
|
|
|
|
|
2018 constant currency revenue growth
|
|
12
|
|
%
|
|
|
|
13
|
|
%
|
FORECASTED 2018 ADJUSTED EARNINGS PER SHARE RECONCILIATION
|
|
Low |
|
|
|
High |
|
|
|
|
|
|
|
|
GAAP diluted earnings per share attributable to common shareholders
|
|
$5.45
|
|
|
|
|
|
$5.55
|
|
|
|
|
|
|
|
|
Restructuring, restructuring related and impairment items, net of tax
|
|
$1.51
|
|
|
|
|
|
$1.55
|
|
|
|
|
|
|
|
|
Acquisition, integration and divestiture related items, net of tax
|
|
$0.26
|
|
|
|
|
|
$0.28
|
|
|
|
|
|
|
|
|
|
|
Other items, net of tax
|
|
$0.01
|
|
|
|
|
|
$0.02
|
|
|
|
|
|
|
|
|
|
|
Intangible amortization expense, net of tax
|
|
$2.47
|
|
|
|
|
|
$2.50
|
|
|
|
|
|
|
|
|
Adjusted diluted earnings per share
|
|
$9.70
|
|
|
|
|
|
$9.90
|
FORECASTED 2019 THROUGH 2021 AVERAGE ANNUAL FREE CASH FLOW GENERATION
Dollars
in Millions
|
|
Low
|
|
|
|
High
|
|
|
|
|
|
|
|
|
Forecasted net cash provided by operating activities from continuing
operations
|
|
$590
|
|
|
|
$620
|
|
|
|
|
|
|
|
|
Forecasted capital expenditures
|
|
$90
|
|
|
|
$70
|
|
|
|
|
|
|
|
|
Forecasted Free Cash Flow
|
|
$500
|
|
|
|
$550
|
ANALYST & INVESTOR DAY WEBCAST
The live webcast of the 2018 Investor & Analyst Day presentations,
including slide presentations, will be available on the Company’s
website: www.teleflex.com.
A replay of the presentations and any related materials will be
available on the Company’s website following the conclusion of the event.
ABOUT TELEFLEX INCORPORATED
Teleflex is a global provider of medical technologies designed to
improve the health and quality of people’s lives. We apply purpose
driven innovation – a relentless pursuit of identifying unmet clinical
needs – to benefit patients and healthcare providers. Our portfolio is
diverse, with solutions in the fields of vascular and interventional
access, surgical, anesthesia, cardiac care, interventional urology,
urology, emergency medicine and respiratory care. Teleflex employees
worldwide are united in the understanding that what we do every day
makes a difference. For more information, please visit teleflex.com.
Teleflex is the home of Arrow®, Deknatel®, Hudson RCI®, LMA®, Pilling®,
Rusch®, UroLift® and Weck® – trusted brands united by a common sense of
purpose.
NOTES ON NON-GAAP FINANCIAL MEASURES
We report our financial results in accordance with accounting principles
generally accepted in the United States, commonly referred to as “GAAP.”
In this press release, we provide supplemental information, consisting
of the following non-GAAP financial measures: adjusted diluted earnings
per share, constant currency revenue growth, organic constant currency
revenue growth, adjusted gross margin expansion, adjusted operating
margin expansion, adjusted tax rate and free cash flow. These non-GAAP
measures are described in more detail below. Management uses these
financial measures to assess Teleflex’s financial performance, make
operating decisions, allocate financial resources, provide guidance on
possible future results, formulate business strategy and assist in its
evaluation of period-to-period and peer comparisons. The non-GAAP
measures may be useful to investors because they provide insight into
management’s assessment of our business, and provide supplemental
information pertinent to a comparison of period-to-period results of our
ongoing operations. The non-GAAP financial measures are presented in
addition to guidance presented in accordance with GAAP and should not be
relied upon as a substitute for GAAP financial measures. Moreover, our
non-GAAP financial measures may not be comparable to similarly titled
measures used by other companies.
Tables reconciling forecasted 2018 constant currency revenue growth,
forecasted 2018 adjusted earnings per share and our goals related to
free cash flow growth per year through 2021 to the most directly
comparable GAAP measures are set forth above. We have not provided a
reconciliation of our goals related to constant currency revenue growth
or organic constant currency revenue growth through 2021 to the most
directly comparable GAAP measure because future changes in foreign
exchange rates over the 2019-2021 period are not reasonably predictable.
Similarly, we have not provided a reconciliation of our goals related to
expansion of adjusted gross and operating margins or the adjusted tax
rate during the three year period through 2021 to the most comparable
GAAP measures because, in each case, the calculation of the GAAP measure
would involve the addition of items (such as restructuring,
restructuring related and impairment items, as well as acquisition,
integration and divestiture related items) the occurrence or amount of
which over the 2019-2021 period are not reasonably predictable.
Adjusted diluted earnings per share: This non-GAAP measure is
based upon diluted earnings per share available to common stockholders,
the most directly comparable GAAP measure, adjusted to exclude,
depending on the period presented, the impact (net of tax) of (i)
restructuring, restructuring related and impairment items; (ii)
acquisition, integration and divestiture related items; (iii) additional
items, such as gains or losses associated with settlements of litigation
that do not arise in the ordinary course, or reversal of contingent
consideration liabilities ; (iv) intangible amortization expense; (v)
loss on extinguishment of debt; and (vi) tax adjustments to eliminate
the impact of the expiration of applicable statutes of limitations for
prior year returns, the resolution of audits and the filing of amended
tax returns with respect to prior tax years and/or tax law changes
affecting the Company’s deferred tax liability. Management does not
believe that any of the excluded items are indicative of our underlying
core performance or business trends.
Constant currency revenue growth: This non-GAAP measure is based
upon net revenues, adjusted to eliminate the impact of translating the
results of international subsidiaries at different currency exchange
rates from period to period. The impact of changes in foreign currency
exchange rates may vary significantly from period to period, and
generally are outside of the control of our management. We believe that
this measure facilitates a comparison of our operating performance
exclusive of fluctuations that do not reflect our underlying performance
or business trends.
Organic constant currency revenue growth: This non-GAAP measure
is based upon constant currency revenue growth, further adjusted to
eliminate the impact of net revenues from acquired businesses during the
first 12 months following the acquisition (for acquired distributors, we
make these adjustments only with respect to non-Teleflex products that
were previously sold by the distributor and that we continued to sell
following the acquisition). We believe this measure facilitates an
assessment of the performance of our legacy businesses, exclusive of
businesses we acquired during the preceding 12 months.
Adjusted gross and operating margins: These non-GAAP measures are
based upon gross margin and operating margin, respectively, adjusted to
exclude, depending on the period presented, the impact of (i)
restructuring, restructuring related and impairment items; (ii)
acquisition, integration and divestiture related items; and (iii)
certain additional items, such as relabeling costs and reversals of
previously recognized income due to distributor acquisitions. Management
does not believe that any of the excluded items are indicative of our
underlying core performance or business trends.
Adjusted tax rate: This non-GAAP measure is based upon (a)
calculating adjusted income from continuing operations by eliminating
the effect of the items listed in the discussion of adjusted diluted
earnings per share above from income from continuing operations; (b)
calculating adjusted taxes on adjusted income from continuing operations
by eliminating the tax effect of the items eliminated in calculating
adjusted income from continuing operations; and (c) determining the
percentage of adjusted income from continuing operations represented by
adjusted taxes on adjusted income from continuing operations. The
calculation of the adjusted tax rate enables adjustments to
appropriately reflect the tax effect of the eliminations made in
calculating adjusted income from continuing operations .
Free Cash Flow: This non-GAAP measure is based upon cash flow
from continuing operations, adjusted to exclude capital expenditures.
Management believes that free cash flow is a useful measure to investors
because it facilitates an assessment of funds available to satisfy
current and future obligations, pay dividends and fund acquisitions. We
also use this financial measure for internal managerial purposes and to
evaluate period-to-period comparisons. Free cash flow is not a measure
of cash available for discretionary expenditures since we have certain
non-discretionary obligations, such as debt service, that are not
deducted from the measure.
CAUTION CONCERNING FORWARD-LOOKING INFORMATION
This press release contains forward-looking statements, including, but
not limited to, forecasted 2018 GAAP and constant currency revenue
growth and forecasted 2018 GAAP and adjusted diluted earnings per share.
Actual results could differ materially from those in the forward-looking
statements due to, among other things, changes in business relationships
with and purchases by or from major customers or suppliers; delays or
cancellations in shipments; demand for and market acceptance of new and
existing products; our inability to integrate acquired businesses into
our operations, realize planned synergies and operate such businesses
profitably in accordance with our expectations; the inability of
acquired businesses to generate revenues in accordance with our
expectations; our inability to effectively execute our restructuring
programs; our inability to realize anticipated savings from
restructuring plans and programs; the impact of healthcare reform
legislation and proposals to amend the legislation; changes in Medicare,
Medicaid and third party coverage and reimbursements; competitive market
conditions and resulting effects on revenues and pricing; increases in
raw material costs that cannot be recovered in product pricing; global
economic factors, including currency exchange rates, interest rates,
sovereign debt issues and the impact of the United Kingdom's vote to
leave the European Union; difficulties in entering new markets; general
economic conditions; and other factors described or incorporated in our
filings with the Securities and Exchange Commission, including our most
recently filed Annual Report on Form 10-K.
CAUTION CONCERNING GOALS AND OBJECTIVES
The goals and objectives set forth in this press release do not
constitute forecasts but, as their name implies, constitute aspirational
goals established by management with regard to our performance over the
2019-2021 period. Management believes that the goals and objectives are
appropriate based on its current view of our business and prospects in
advance of the 2019-2021 period, but are subject to a variety of risks,
including, among others, those set forth in discussion of
forward-looking statements above, as well as the possibility that
subsequent developments may lead management to adopt different business
plans and strategies than those underlying the goals and objectives
described above.
Teleflex, the Teleflex logo, Arrow, Deknatel, Hudson RCI, LMA,
Pilling, Rüsch, and Weck are trademarks or registered trademarks of
Teleflex Incorporated or its affiliates, in the U.S. and/or other
countries.

View source version on businesswire.com: https://www.businesswire.com/news/home/20180511005015/en/
Source: Teleflex Incorporated
Teleflex Incorporated
Jake Elguicze
Treasurer and Vice
President, Investor Relations
610-948-2836